Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
NORGESTIMATE (UNII: C291HFX4DY) (NORGESTIMATE - UNII:C291HFX4DY), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Aurobindo Pharma Limited
NORGESTIMATE
NORGESTIMATE 0.180 mg
PRESCRIPTION DRUG
Tri-Lo-Mili (norgestimate and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy [see Clinical Studies (14)] . Tri-Lo-Mili (norgestimate and ethinyl estradiol tablets) is contraindicated in females who are known to have or develop the following conditions: - A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1)] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)] Have cerebrovascular disease [see Warnings and Precautions (5.1)] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)
Tri-Lo-Mili (norgestimate and ethinyl estradiol tablets USP) are available in a blister pack. Each blister pack (28 tablets) contains in the following order: The blister packs are available in the following packages: Carton of 1 Blister Pack NDC 65862-778-28 Carton of 3 Blister Packs packaged in mono cartons NDC 65862-778-85 Carton of 6 Blister Packs packaged in mono cartons NDC 65862-778-86 Carton of 1 Pouch NDC 65862-778-87 Carton of 3 Pouches NDC 65862-778-88 Carton of 6 Pouches NDC 65862-778-92 Keep out of the reach of children.
Abbreviated New Drug Application
TRI-LO-MILI- NORGESTIMATE AND ETHINYL ESTRADIOL AUROBINDO PHARMA LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TRI-LO-MILI® SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TRI-LO-MILI. TRI-LO-MILI (NORGESTIMATE AND ETHINYL ESTRADIOL) TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ TRI-LO-MILI IS CONTRAINDICATED IN WOMEN OVER 35 YEARS OLD WHO SMOKE. (4) CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVES (COC) USE. (4) RECENT MAJOR CHANGES Warnings and Precautions (5.11) 11/2021 INDICATIONS AND USAGE Tri-Lo-Mili (norgestimate and ethinyl estradiol tablets) is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. (1.1) DOSAGE AND ADMINISTRATION Take one tablet daily by mouth at the same time every day. (2.2) Take tablets in the order directed on the blister pack. (2.2) Do not skip or delay tablet intake. (2.2) DOSAGE FORMS AND STRENGTHS Tri-Lo-Mili (norgestimate and ethinyl estradiol tablets USP) consists of 21 round, biconvex, coated tablets and 7 round, mottled, biconvex, uncoated tablets in the following order (3): 7 white to off white tablets each containing 0.180 mg norgestimate and 0.025 mg ethinyl estradiol 7 pale blue to bluish white tablets each containing 0.215 mg norgestimate and 0.025 mg ethinyl estradiol 7 blue to light blue tablets each containing 0.250 mg norgestimate and 0.025 mg ethinyl estradiol 7 green tablets (inert) CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Pregnancy (4) Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (4) WARNINGS AND PRE Pročitajte cijeli dokument